Research programme: heat shock transcription factor stimulants - Chaperone Pharma

Drug Profile

Research programme: heat shock transcription factor stimulants - Chaperone Pharma

Alternative Names: NYK 1112; NYK 1341; NYK-1005; NYK-1007

Latest Information Update: 17 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nyken
  • Developer Chaperone Pharma
  • Class
  • Mechanism of Action Heat shock transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute kidney injury; Delayed graft function
  • Research Atrial fibrillation; Heart failure

Most Recent Events

  • 19 May 2016 Early research development is ongoing for Atrial fibrillation in Netherlands (Nyken pipeline, May 2016)
  • 19 May 2016 NYK 1341 is available for licensing as of May 2016.
  • 19 May 2016 Early research in Heart failure in Netherlands (PO) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top